Skip to Main Content

++

CASE PRESENTATION

++

A 31-year-old woman was admitted in a state of cardiogenic shock 6 months after she was diagnosed with nonischemic cardiomyopathy. Nearly 9 to 12 months ago, she had started experiencing fatigue and dyspnea while climbing stairs and was diagnosed with left ventricular systolic dysfunction a few months later. She had ejection fraction of 15% and dilated left ventricle of 6.8 cm and was started on medicines and evidence-based treatment. More recently, she developed intolerance toward her current carvedilol dose that had to be reduced as it caused hypotension and nausea. Currently, the patient was admitted with blood pressure of 88/62 mm Hg, heart rate of 105 beats per minute, S3 gallop on examination, elevated jugular venous distention to 6 cm above the clavicle, cool extremities, brain natriuretic peptide of 953 pg/mL, serum sodium of 134 mmol/L, and total bilirubin of 4 mg/dL. The physician started her on an inotrope upon admission. After diuresis, her right heart catheterization revealed elevated filling pressures (right atrial pressure of 15 mm Hg, wedge pressure of 36 mm Hg), pulmonary hypertension (mean pulmonary artery pressure of 49 mm Hg), and low cardiac index <1.8 on dobutamine 5 μg/kg/min. Echo now revealed progression of left ventricular dilation to 7.2 cm, moderate mitral regurgitation, and moderate right ventricular dysfunction in addition to left-sided failure. Due to advanced stage of the disease and clinical decline in patient's condition, she was worked up for cardiac transplantation and listed with blood type O. Meanwhile, she continued to decline requiring 2 inotropes, and a repeat hemodynamic evaluation showed a high pulmonary vascular resistance of 4.5 Wood units. Her chances of receiving a cardiac transplant were also limited by both her blood type (type O) and worsening pulmonary hypertension. Besides, she could not tolerate attempts to wean her off the inotrope or pressor support, and continued to become more tachycardic. So a decision was made to implant ventricular assist device that would act as a bridge to cardiac transplantation by extending the life of the patient.

++

INTRODUCTION

++

Heart failure is a complex clinical syndrome with increasing prevalence and incidence in developed and developing nations. Among adults in the United States, heart failure is now the leading etiology for inpatient admissions. Women represent half of these hospital admissions and heart failure accounts for approximately one-third of all deaths from cardiovascular disease in women.1,2,3 Although women bear a significant burden of heart failure mortality and morbidity, they are historically very poorly represented in clinical trials: prior to 2002, only one-fifth of patients enrolled in randomized controlled trials were women.4 Therefore a paucity of evidence exists regarding gender-specific differences in the diagnosis, treatment, and prognosis of heart failure.

++

GENETIC EXPRESSION

++

Recent analysis revealed differential autosomal gene expression in men versus women with heart failure.5,6,7 Women overexpressed genes related to adrenergic and angiotensin signaling, cyclic nucleotide metabolism, and glucose transport (GATAD1, PDE6B, and SCLA12, respectively). Those genes upregulated in men with heart failure were associated with potassium channel/arrhythmia regulation, cellular homeostasis, and immune system regulation (KCNK1, PLEKHA8, and CD24, respectively). These initial genetic studies may provide an early foundation to explain the gender differences noted in etiology (eg, ischemic vs nonischemic secondary to hypertensive heart disease), presentation (eg, with age differences), clinical course, and response to treatment in heart failure—or personalized medicine based on sex-related heart failure management.

++

EPIDEMIOLOGY

++

The prevalence of heart failure increases in both men and women as the population ages. However, the initial diagnosis of heart failure occurs later in women, and more women than men have heart failure after the age of 80.8 The most recent ...

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

AccessCardiology Full Site: One-Year Subscription

Connect to the full suite of AccessCardiology content and resources including textbooks such as Hurst's the Heart and Cardiology Clinical Questions, a unique library of multimedia, including heart imaging, an integrated drug database, and more.

$595 USD
Buy Now

Pay Per View: Timed Access to all of AccessCardiology

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.